What researchers discovered about Crohn's disease in the past year
Autoimmune diseases like Crohn’s are poorly understood by researchers. Scientists are still uncertain about how the body’s immune system attacks perfectly healthy cells to lead to disease like type 1 diabetes, lupus, Crohn’s disease, multiple sclerosis and more. But 2013 has lead to some advances in understanding Crohn’s disease that can lead to better treatment and improved quality of life for those suffering from the condition that can be debilitating.
Understanding Crohn’s disease with fibrosis
Researchers from University of Bristol uncovered the culprit for scarring and hardening of the intestines that can happen with Crohn’s disease and often requires surgery.
Fibrosis causes the intestines to narrow and become thick so nutrients cannot be absorbed and feces can no longer pass.
In their study, the scientists isolated a protein known as IL-13 that is overly expressed that promotes Crohn’s disease fibrosis. The result of the finding will lead to better therapies for the disease that can be started before fibrosis and the need for surgery occurs. The finding was published in the journal PLoS ONE in December, 2012.
New drug therapy on the horizon for Crohn’s disease?
The drug Vedolizumab is currently under development for treating Crohn’s disease.
One of the important highlights of the medication should it pass approval is that preliminary studies show it delivers targeted treatment to stop the inflammatory process that happens with Crohn’s disease and ulcerative colitis, both of which are are forms of inflammatory autoimmune diseases that affect the small intestine and colon.
Current treatments help Crohn’s disease, but with potentially serious side effects such as risk of infection, weight gain and blood sugar elevation that can come from taking steroids. Immunosuppressive medications can also make people more vulnerable to infection and are associated with lymphoma.
William Sandborn, MD, principal investigator of the Crohn's disease study, said the clinical trials so far offer new hope to the more than one million Americans who suffer from inflammatory bowel disease (IBD) and do not respond to treatment. Two studies showed vedolizumab induced remission of the disease that allowed participants to stop taking prednisone.
Genes found for Crohn’s disease